Pharmacokinetic/Physiologically based pharmacokinetic models in integrated risk information system assessments

Toxicokinetics and Risk Assessment

Volumn , Issue , 2016, Pages 301-348

  DeWoskin, Robert S ^a   Lipscomb, John C ^b   Thompson, Chadwick ^b   Chiu, Weihsueh A ^b   Schlosser, Paul ^b   Smallwood, Carolyn ^b   Swartout, Jeff ^b   Teuschler, Linda ^b   Marcus, Allan ^a  

^a U S ENVIRONMENTAL PROTECTION AGENCY   (United States)

^b U S ENVIRONMENTAL PROTECTION AGENCY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85122908878     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (103)

1. U.S. EPA, Integrated Risk Information System (IRIS). Washington, D.C.: U.S. Environmental Protection Agency, National Center for Environmental Assessment, 2005. Available at http://www.epa.gov/iris.
2. Krishnan K, Andersen ME. Physiologically based pharmacokinetic modeling in toxicology. In: Hayes AW, ed. Principles and methods of toxicology. Philadelphia: Taylor & Francis, 2001:193-241.
3. Gentry PR, Covington TR, Andersen ME, et al. Application of a physiologically based pharmacokinetic model for isopropanol in the derivation of a reference dose and reference concentration. Regul Toxicol Pharmacol 2002; 36: 51-68.
4. Dorne JL. Impact of inter-individual differences in drug metabolism and pharmacokinetics on safety evaluation. Fundam Clin Pharmacol 2004; 18:609-620.
5. Ginsberg G, Hattis D, Sonawane B. Incorporating pharmacokinetic differences between children and adults in assessing children's risks to environmental toxicants. Toxicol Appl Pharmacol 2004; 198:164-183.
6. Hattis D, Banati P, Goble R. Distributions of individual susceptibility among humans for toxic effects. How much protection does the traditional tenfold factor provide for what fraction of which kinds of chemicals and effects? Ann N Y Acad Sci 1999; 895:286-316.
7. Krishnan K, Johanson G. Physiologically-based pharmacokinetic and toxicokinetic models in cancer risk assessment. J Environ Sci Health C Environ Carcinog Ecotoxical Rev 2005; 23:31-53.
8. Clark LH, Setzer RW, Barton HA. Framework for evaluation of physiologically-based pharmacokinetic models for use in safety or risk assessment. Risk Anal 2004; 24:1697-1717.
9. U.S. EPA, Toxicological Review of Chloroform, EPA/635/R-01/001, U.S. Environmental Protection Agency, Integrated Risk Information System, Washington, D.C., 2001. Available at http://www.epa.gov/iriswebp/iris/index.html.
10. Heywood R, Sortwell RJ, Noel PR, et al. Safety evaluation of toothpaste containing chloroform: III. Long-term study in beagle dogs. J Environ Pathol Toxicol 1979; 2:835-851.
11. Corley RA, Mendrela AL, Smith FA, et al. Development of a physiologically based pharmacokinetic model for chloroform. Toxicol Appl Pharmacol 1990; 103:512-527.
12. Reitz RH, Mendrela AL, Corley RA, et al. Estimating the risk of liver cancer associated with human exposures to chloroform using physiologically-based pharmacokinetic modeling. Toxicol Appl Pharmacol 1990; 105:443-459.
13. U.S. EPA, Toxicological Review of Methyl Ethyl Ketone, EPA/635/R-03/009, U.S. Environmental Protection Agency, Integrated Risk Information System, Washington, D.C., 2003. Available at http://www.epa.gov/iriswebp/iris/index.html.
14. Liira J, Johanson G, Riihimaki V. Dose-dependent kinetics of inhaled methyl ethyl ketone in man. Toxicol Lett 1990b; 50:195-201.
15. Leung H-W. Use of physiologically based pharmacokinetic models to establish biological exposure indices. Am Ind Hyg Assoc J 1992; 53:369-374.
16. Dietz FK, Rodriguez-Giaxola M, Traiger GJ, et al. Pharmacokinetics of 2-butanol and its metabolites in the rat. J Pharmacokinet Biopharm 1981; 9:553-576.
17. Thrall KD, Soelberg JJ, Weitz KK, et al. Development of a physiologically based pharmacokinetic model for methyl ethyl ketone in F344 rats. J Toxicol Environ Health A 2002; 65:881-896.
18. Traiger GJ, Bruckner JV. The participation of 2-butanone in 2-butanol-induced potentiation of carbon tetrachloride hepatotoxicity. J Pharmacol Exp Ther 1976; 196:493-500.
19. Dietz FK, Traiger GJ. Potentiation of CCl4 of hepatotoxicity in rats by a metabolite of 2-butanone: 2,3-butanediol. Toxicology 1979; 14:209-215.
20. U.S. EPA, Toxicological Review of Acetone, EPA/635/R-03/004, U.S. Environmental Protection Agency, Integrated Risk Information System, Washington, D.C., 2003. Available at http://www.epa.gov/iriswebp/iris/index.html.
21. Clewell HJ III, Gentry PR, Gearhart JM, et al. Development of a physiologically based pharmacokinetic model of isopropanol and its metabolite acetone. Toxicol Sci 2001; 63:160-172.
22. Kumagai S, Matsunaga I. Physiologically based pharmacokinetic model for acetone. Occup Environ Med 1995; 52:344-352.
23. NTP (National Toxicology Program), Toxicity Studies of Acetone (CAS No. 67-64-1) in F344/N Rats and B6C3F1 Mice (drinking water studies), NTP TOX 3. Research Triangle Park, NC: U.S. Department of Health and Human Services, Public Health Service, National Institutes of Health, 1991 [NIH Publication No. 91-3122].
24. Dietz DD, Leninger JR, Rauckman EJ, et al. Toxicity studies of acetone administered in the drinking water of rodents. Fundam Appl Toxicol 1991; 17: 347-360.
25. Gentry PR, Covington TR, Clewell HJ III, Anderson ME. Application of a physiologically based pharmacokinetic model for reference dose and reference concentration estimation for acetone. J Toxicol Environ Health A 2003; 66:2209-2225.
26. U.S. EPA, Toxicological Review of Ethylene Glycol Monobutyl Ether (EGBE), U.S. Environmental Protection Agency, Integrated Risk Information System, Washington, D.C., 1999.
27. Corley RA, Bormett GA, Ghanayem BI. Physiologically-based pharmacokinetics of 2-butoxyethanol and its major metabolite, 2-butoxyacetic acid, in rats and humans. Toxicol Appl Pharmacol 1994; 129:61-79.
28. Johanson G, Wallen M, Nordquist MB. Elimination kinetics of 2-butoxyethanol in the perfused rat liver-dose dependence and effect of ethanol. Toxicol Appl Pharmacol 1986; 83:315-320.
29. Corley RA, Markham DA, Banks C, et al. Physiologically based pharmacokinetics and the dermal absorption of 2-butoxyethanol vapor by humans. Fundam Appl Toxicol 1997; 39:120-130.
30. NTP (National Toxicology Program), Technical Report on Toxicity Studies of Ethylene Glycol Ethers 2-Methoxyethanol, 2-Ethoxyethanol, 2-Butoxyethanol Administered in Drinking Water to F344/N Rats and B6C3F1 Mice, NTP No. 26. Research Triangle Park, NC: U.S. Department of Health and Human Services, Public Health Service, National Institutes of Health, 1993 [NIH Publication No. 93-3349].
31. NTP (National Toxicology Program), NTP Technical Report on the Toxicology and Carcinogenesis Studies of 2-Butoxyethanol (CAS No. 111-76-2) in F344/N Rats and B6C3F1 Mice (inhalation studies), NTP TR 484. Research Triangle Park, NC: U.S. Department of Health and Human Services, Public Health Service, National Institutes of Health, 1998 [NIH Draft Publication No. 98-3974].
32. Deisinger PJ, Boatman RJ. In vivo metabolism and kinetics of ethylene glycol monobutyl ether and its metabolites, 2-butoxyacetaldehyde and 2-butoxyacetic acid, as measured in blood, liver and forestomach of mice. Xenobiotica 2004; 34(7):675-685.
33. U.S. EPA, Toxicological Review of Vinyl Chloride, EPA/635/R-00/004. Washington, D.C.: U.S. Environmental Protection Agency, Integrated Risk Information System, 2000.
34. Clewell HJ III, Gentry PR, Gearhart JM, et al. The development and validation of a physiologically based pharmacokinetic model for vinyl chloride and its application in a carcinogenic risk assessment for vinyl chloride. Washington, D.C.: ICF Kaiser for the U.S. Environmental Protection Agency, Office of Health and Environmental Assessment, and the Occupational Safety and Health Administration, Directorate of Health and Standards Programs, 1995.
35. Clewell HJ III, Covington TR, Crump KS, et al. The application of a physiologically based pharmacokinetic model for vinyl chloride in a noncancer risk assessment. Washington, D.C.: ICF Kaiser/Clement Associates under EPA contract number 68-D2-0129 for the U.S. Environmental Protection Agency, National Center for Environmental Assessment, 1995.
36. D'Souza RW, Andersen ME. Physiologically based pharmacokinetic model for vinylidene chloride. Toxicol Appl Pharmacol 1988; 95:230-240.
37. Andersen ME, Clewell HJ, Gargas ML, et al. Physiologically based pharmaco-kinetics and risk assessment process for methylene chloride. Toxicol Appl Pharmacol 1987; 87:185-205.
38. U.S. EPA. Recommendations for and Documentation of Biological Values for Use in Risk Assessment, EPA/600/6-87/008. NTIS PB88-179874/AS. Washington, D.C.: U.S. Environmental Protection Agency, 1988.
39. Gargas ML, Burgess RJ, Voisard DE, et al. Partition coefficients of low-molecular-weight volatile chemicals in various liquids and tissues. Toxicol Appl Pharmacol 1989; 98:87-99.
40. Barton HA, Creech JA, Godin CS, et al. Chloroethylene mixtures: pharmaco-kinetic modeling and in vitro metabolism of vinyl chloride, trichloroethylene, and trans-1,2-dichloroethylene in the rat. Toxicol Appl Pharmacol 1995; 130:237-247.
41. Andersen ME, Gargas ML, Clewell HJ, et al. Quantitative evaluation of the metabolic interactions between trichloroethylene and 1,1-dichloroethylene in vivo using gas uptake methods. Toxicol Appl Pharmacol 1987; 89:149-157.
42. Bolt HM, Lai RJ, Kappus H, et al. Pharmacokinetics of vinyl chloride in the rat. Toxicology 1977; 7:179-188.
43. Clement International, Development, and Validation of Methods for Applying Pharmacokinetic Data in Risk Assessment. Final Report. Vol. V: Vinyl Chloride, AAMRL-TR-90-072. Dayton, OH: Department of the Air Force, Armstrong Aerospace Medical Research Laboratory, Wright-Patterson Air Force Base, 1990.
44. Gargas ML, Clewell HJ III, Andersen ME. Gas uptake inhalation techniques and the rates of metabolism of chloromethanes, chloroethanes, and chloroethy-lenes in the rat. Inhal Toxicol 1990; 2:295-319.
45. Buchter A, Filser JG, Peter H, et al. Pharmacokinetics of vinyl chloride in the Rhesus monkey. Toxicol Lett 1980; 6:33-36.
46. Kedderis GL, Carfagna MA, Held SD, et al. Kinetic analysis of furan biotransformation by F-344 rats in vivo and in vitro. Toxicol Appl Pharmacol 1993; 123:274-282.
47. Til HP, Immel HR, Feron FJ. Lifespan Oral Carcinogenicity Study of Vinyl Chloride in Rats, TNO Report no. V 83.285/291099. Zeist, The Netherlands: Netherlands Organization for Applied Scientific Research, Division for Nutrition and Food Research TNO, 1983.
48. Til HP, Feron VJ, Immel HR. Lifetime (149-week) oral carcinogenicity study of vinyl chloride in rats. Food Chem Toxicol 1991; 29:713-718.
49. U.S. EPA. Health Effects Assessment Summary Tables (HEAST), EPA/540/ R-97/036, Washington, D.C.: U.S. Environmental Protection Agency, Office of Solid Waste and Emergency Response, 1997.
50. U.S. EPA Health Effects Assessment Summary Tables (HEAST). EPA/540R-97/036. U.S. Environmental Protection Agency, Office of Solid Waste and Emergency Response, Washington, D.C., 1997.
51. U. S. EPA, Health Assessment Document for Dichloromethane (Methylene Chloride). Final Report, EPA/600/8-82/004F, U.S. Environmental Protection Agency, Office of Health and Environmental Assessment, Washington, D.C., 1985.
52. U.S. EPA, Addendum to the Health Assessment Document for Dichloromethane (methylene chloride). Updated Carcinogenicity Assessment, EPA/600/8-82/ 004FF, Carcinogen Assessment Group, OHEA for the U.S. Environmental Protection Agency, Washington, D.C., 1985.
53. U.S. EPA, Update to the Health Assessment Document and Addendum for Dichloromethane (Methylene Chloride): Pharmacokinetics, Mechanism of Action and Epidemiology. Review Draft, EPA/600/8-87/030A, U.S. Environmental Protection Agency, Office of Health and Environmental Assessment, Washington, D.C., 1987.
54. U.S. EPA, Technical Analysis of New Methods and Data Regarding Dichlor-omethane Hazard Assessments. Review Draft, EPA/600/8-87/029A, U.S. Environmental Protection Agency, Office of Health and Environmental Assessment, Washington, D.C., 1987.
55. Andersen ME, Clewell HJ, Gargas ML, et al. Physiologically based pharmaco-kinetic modeling with dichloromethane, its metabolite, carbon monoxide, and blood carboxyhemoglobin in rats and humans. Toxicol Appl Pharmacol 1991; 108:14-27.
56. Ramsey JC, Andersen ME. A physiologically based description of the inhalation pharmacokinetics of styrene in rats and humans. Toxicol Appl Pharmacol 1984; 73:159-175.
57. NTP (National Toxicology Program), Toxicology and Carcinogenesis Studies of Dichloromethane (methylene chloride)(CAS No. 75-09-2) in F344/N Rats and B6C3F1 Mice (inhalation studies), NTP-TR-306. Research Triangle Park, NC: U.S. Department of Health and Human Services, Public Health Service, National Institutes of Health, 1986 [NIH Publication No. 86-2562].
58. NCA (National Coffee Association), Twenty-four Month Oncogenicity Study of Methylene Chloride in Mice. Final Report, Hazleton Laboratories, America, Inc., Vienna, VA, 1983.
59. Thomas RS, Yang RS, Morgan DG, et al. PBPK modeling/Monte Carlo simulation of methylene chloride kinetic changes in mice in relation to age and acute, subchronic, and chronic inhalation exposure. Environ Health Perspect 1996; 104:858-865.
60. El-Masri HA, Bell DA, Portier CJ. Effects of glutathione transferase theta polymorphism on the risk estimates of dichloromethane to humans. Toxicol Appl Pharmacol 1999; 158:221-230.
61. Jonsson F, Johanson G. A Bayesian analysis of the influence of GSTT1 polymorphism on the cancer risk estimate for dichloromethane. Toxicol Appl Pharmacol 2001; 174:99-112.
62. Jonsson F, Bois F, Johanson G. Physiologically based pharmacokinetic modeling of inhalation exposure of humans to dichloromethane during moderate to heavy exercise. Toxicol Sci 2001; 59:209-218.
63. Sweeney LM, Kirman CR, Morgott DA, et al. Estimation of interindividual variation in oxidative metabolism of dichloromethane in human volunteers. Toxicol Lett 2004; 154:201-216.
64. ENVIRON Health Sciences Institute. Development of Population Cancer Risk Estimates for Environmental Exposure to Methylene Chloride (DCM) Using a Physiologically Based Pharmacokinetic Model. Ruston, LA: ENVIRON Health Sciences Institute, 2005.
65. Starr TB, Matanoski G, Anders MW, et al. Workshop overview: reassessment of the cancer risk of dichloromethane in humans. Toxicol Sci 2006; 91:20-28.
66. Tardif R, Lapare S, Plaa GL, et al. Effect of simultaneous exposure to toluene and xylene on their respective biological exposure indices in humans. Int Arch Occup Environ Health 1991; 63:279-284.
67. Tardif R, Plaa GL, Brodeur J. Influence of various mixtures of inhaled toluene and xylene on the biological monitoring of exposure to these solvents in rats. Can J Physiol Pharmacol 1992; 70:385-393.
68. Tardif R, Lapare S, Krishnan K, et al. Physiologically based modeling of the toxicokinetic interaction between toluene and m-xylene in the rat. Toxicol Appl Pharmacol 1993; 120:266-273.
69. Kaneko T, Horicuhi J, Sato A. Development of a physiologically based pharmacokinetic model of organic solvent in rats. Pharmacol Res 2000; 42: 465-470.
70. Tardif R, Lapare S, Krishnan K, et al. A descriptive and mechanistic study of the interaction between toluene and xylene in humans. Int Arch Occup Environ Health 1993; 65:S135-S137.
71. Tardif R, Lapare S, Charest-Tardif G, et al. Physiologically-based pharmaco-kinetic modeling of a mixture of toluene and xylene in humans. Risk Anal 1995; 15:335-342.
72. Haddad S, Tardif R, Viau C, et al. A modeling approach to account for toxicokinetic interactions in the calculation of biological hazard index for chemical mixtures. Toxicol Lett 1999; 108:303-308.
73. Tardif R, Charest-Tardif G, Brodeur J, et al. Physiologically based pharmacokinetic modeling of a ternary mixture of alkyl benzenes in rats and humans. Toxicol Appl Pharmacol 1997; 144:120-134.
74. U.S. EPA, Methods for Derivation of Inhalation Reference Concentrations and Application of Inhalation Dosimetry, EPA/600/8-90/066F, U.S. Environmental Protection Agency, Office of Research and Development, Washington, D.C., 1994. Available at http://nepis.epa.gov/pubtitleORD.htm.
75. Korsak Z, Wisniewska-Knypl J, Swiercz R. Toxic effects of subchronic combined exposure to n-butyl alcohol and m-xylene in rats. Int J Occup Med Environ Health 1994; 7:155-166.
76. Korsak Z, Sokal JA, Gorny R. Toxic effects of combined exposure to toluene and m-xylene in animals. III. Subchronic inhalation study. Pol J Occup Med Environ Health 1992; 5:27-33.
77. Dennison JE, Bigelow PL, Mumtaz MM, et al. Evaluation of potential toxicity from co-exposure to three CNS depressants (toluene, ethylbenzene, and xylene) under resting and working conditions using PBPK modeling. J Occup Environ Hyg 2005; 2:127-135.
78. Dennison JE, Andersen ME, Yang RS. Characterization of the pharmacoki-netics of gasoline using PBPK modeling with a complex mixtures chemical lumping approach. Inhal Toxicol 2003; 15:961-986.
79. WHO (World Health Organization). Environmental Health Criteria 204: Boron. Geneva, Switzerland: World Health Organization, 1998.
80. IPCS (International Programme on Chemical Safety), Guidance Document for the Use of Data in Development of Chemical-specific Adjustment Factors (CSAF) for Interspecies Differences and Human Variability in Dose/concentration Response Assessment, World Health Organization, Geneva, Switzerland, 2001. Available at www.who.int/entity/ipcs/publications/methods/harmonization/en/csafs_guidance:doc.pdf.
81. U.S. EPA, Integrated Risk Information System (IRIS), Online Toxicological Review of Boron and Compounds (CASRN 7440-42-8), entered August 2004, U.S. Environmental Protection Agency, Integrated Risk Information System, Washington, D.C., 2006. Available at http://www.epa.gov/iris/subst/0410.htm.
82. Heindel JJ, Price CJ, Field EA, et al. Developmental toxicity of boric acid in mice and rats. Fundam Appl Toxicol 1992; 18:266-277.
83. Price CJ, Strong PL, Marr MC, et al. Developmental toxicity NOAEL and postnatal recovery in rats fed boric acid during gestation. Fundam Appl Toxicol 1996; 32:179-193.
84. Allen BC, Strong PL, Price CJ, et al. Benchmark dose analysis of developmental toxicity in rats exposed to boric acid. Fund Appl Toxicol 1996; 32:194-204.
85. Schou JS, Jansen JA, Aggerbeck B. Human pharmacokinetics and safety of boric acid. Arch Toxicol Suppl 1984; 7:232-235.
86. Ku WW, Chapin RE, Moseman RF, et al. Tissue disposition of boron in male Fischer rats. Toxicol Appl Pharmacol 1991; 111:145-151.
87. Vaziri ND, Oveisi F, Culver BD, et al. The effect of pregnancy on renal clearance of boron in rats given boric acid orally. Toxicol Sci 2001; 60:257-263.
88. Pahl MV, Culver BD, Strong PL, et al. The effect of pregnancy on renal clearance of boron in humans: a study based on normal dietary intake of boron. Toxicol Sci 2001; 60:252-256.
89. Jansen JA, Schou JS, Aggerback A. Gastrointestinal absorption and in vitro release of boric acid from water emulsifying ointments. Food Chem Toxicol 1984; 22:49-53.
90. Jansen JA, Andersen J, Schou JS. Boric acid single dose pharmacokinetics after intravenous administration to man. Arch Toxicol 1984; 55:64-67.
91. Dunlop W. Serial changes in renal haemodynamics during normal human pregnancy. Br J Obstet Gynecol 1981; 88:1-9.
92. Sturgiss SN, Wilkinson R, Davison JM. Renal reserve during human pregnancy. Am J Physiol 1996; 271:F16-F20.
93. Krutzen F, Olofsson P, Beck SE, et al. Glomerular filtration rate in pregnancy; a study in normal subjects and in patients with hypertension, preeclampsia and diabetes. Scand J Clin Lab Invest 1992; 52:387-392.
94. Dourson M, Maier A, Meek B, et al. Boron tolerable intake re-evaluation of toxicokinetics for data derived uncertainty factors. Biol Trace Elem Res 1998; 66:453-463.
95. Needleman H. Lead poisoning. Ann Rev Med 2004; 55:209-222.
96. Nriagu Jerome O. Lead and Lead Poisoning in Antiquity. John Wiley & Sons. New York, NY, U.S.A. 1983.
97. U.S. EPA, Guidance Manual for the Integrated Exposure Uptake Biokinetic Model for Lead in Children, EPA/540/R-93/081, PB93-963510, U.S. Environmental Protection Agency, Washington, D.C., 1994.
98. U.S. EPA, Technical Support Document: Parameters and Equations Used in the Integrated Exposure, Uptake, and Biokinetic Model for Lead in Children (v0.99d), EPA/540/R-94/040, NTIS PB94-963505, U.S. Environmental Protection Agency, Washington, D.C., 1994. Available at http://www.epa.gov/superfund/programs/lead/products.htm.
99. Hogan K, Marcus A, Smith R, et al. Integrated exposure uptake model for lead in children: empirical comparisons with epidemiologic data. Environ Health Perspect 1998; 106:1557-1567.
100. Marcus AH, Elias RW. Some useful statistical methods for model validation. Environ Health Perspect 1998; 106:1541-1550.
101. Mickle MH. Structure, use, and validation of the IEUBK model. Environ Health Perspect 1998; 106:1531-1534.
102. White PD, Van Leeuwen P, Davis BD, et al. The conceptual structure of the integrated exposure uptake biokinetic model for lead in children. Environ Health Perspect 1998; 106:1495-1503.
103. U.S. EPA, Guidance Manual for the All Ages Lead Model (AALM). Draft Version 1.05, EPA/600/C-05/013, U.S. Environmental Protection Agency, Washington, D.C., 2005. Available at http://cfpub.epa.gov/ncea/cfm/recordisplay.cfm?deid= 139314.